TScan Therapeutics - TCRX Short Interest Ratio & Short Volume

Short interest is the volume of TScan Therapeutics shares that have been sold short but have not yet been closed out or covered. As of January 15th, investors have sold 144,900 shares of TCRX short. 1.58% of TScan Therapeutics' shares are currently sold short. Learn More on TScan Therapeutics' current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. TCRX shares currently have a short interest ratio of 1.0. Learn More on TScan Therapeutics's short interest ratio.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 1.58% of TScan Therapeutics' floating shares are currently sold short.

TScan Therapeutics saw a drop in short interest during the month of January. As of January 15th, there was short interest totaling 144,900 shares, a drop of 1.6% from the previous total of 147,200 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

TScan Therapeutics currently has issued a total of 24,080,000 shares. Some of TScan Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. TScan Therapeutics currently has a public float of 9,160,000 shares.

1.58% of TScan Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "biological products, except diagnostic" compare to TScan Therapeutics: Achilles Therapeutics plc (0.20%), Cardiol Therapeutics Inc. (0.42%), Axcella Health Inc. (1.20%), BioCardia, Inc. (0.42%), AVROBIO, Inc. (0.35%), Dyadic International, Inc. (2.25%), IN8bio, Inc. (1.52%), Evaxion Biotech A/S (0.13%), Protara Therapeutics, Inc. (0.97%), and TRACON Pharmaceuticals, Inc. (1.67%).

As of the most recent reporting period, the following stocks had the largest short interest positions: Occidental Petroleum Co. ($3.43 billion), T. Rowe Price Group, Inc. ($2.26 billion), Coinbase Global, Inc. ($2.19 billion), Etsy, Inc. ($1.78 billion), Paramount Global ($1.77 billion), Old Dominion Freight Line, Inc. ($1.69 billion), United Rentals, Inc. ($1.53 billion), American Airlines Group Inc. ($1.52 billion), PG&E Co. ($1.48 billion), and Voya Financial, Inc. ($1.47 billion). View all of the most shorted stocks.

Short selling TCRX is an investing strategy that aims to generate trading profit from TScan Therapeutics as its price is falling. TCRX shares are trading up $0.06 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for TScan Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of TCRX, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including TCRX, twice per month. The most recent reporting period available is January, 15 2023.